Nkarta (NKTX) Total Liabilities (2019 - 2026)
Nkarta (NKTX) posted quarterly Total Liabilities of $86.2 million for Q1 2026, down 6.09% year-over-year from $91.8 million in Q1 2025, and down 6.17% quarter-over-quarter from $91.9 million in Q4 2025.
Nkarta (NKTX) Total Liabilities (2019 - 2026) Analysis & Trends
Nkarta's Total Liabilities history runs 8 years deep, the most recent figure standing at $86.2 million for Q1 2026.
- In Q1 2026, Total Liabilities fell 6.09% year-over-year to $86.2 million; the TTM figure through Mar 2026 stood at $86.2 million (down 6.09% YoY), while the FY2025 annual figure was $91.9 million, down 1.44% from the prior year.
- Total Liabilities for Q1 2026 stood at $86.2 million, down from $91.9 million in the prior quarter.
- The five-year high for Total Liabilities was $111.5 million in Q1 2023, with the low at $77.6 million in Q1 2022.
- The 5-year median for Total Liabilities is $100.7 million (2022), against an average of $97.1 million.
- The sharpest annual moves came in 2022 and 2024: Total Liabilities surged 365.55% in 2022, then fell 11.72% in 2024.
- Nkarta's Total Liabilities stood at $100.7 million in 2022, then climbed by 4.83% to $105.6 million in 2023, then retreated by 11.72% to $93.2 million in 2024, then decreased by 1.44% to $91.9 million in 2025, then decreased by 6.17% to $86.2 million in 2026.
- Business Quant data shows NKTX's Total Liabilities at $86.2 million in Q1 2026, $91.9 million in Q4 2025, and $89.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Nkarta | 201.14 Mn | 201.14 Mn | - | 89.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 89.91 Mn |
| Mar 31, 2026 | 86.21 Mn |
| Dec 31, 2025 | 91.88 Mn |
| Sep 30, 2025 | 89.34 Mn |
| Jun 30, 2025 | 90.64 Mn |
| Mar 31, 2025 | 91.80 Mn |
| Dec 31, 2024 | 93.23 Mn |
| Sep 30, 2024 | 101.16 Mn |
| Jun 30, 2024 | 100.90 Mn |
| Mar 31, 2024 | 103.29 Mn |
| Dec 31, 2023 | 105.60 Mn |
| Sep 30, 2023 | 109.05 Mn |
| Jun 30, 2023 | 111.06 Mn |
| Mar 31, 2023 | 111.52 Mn |
| Dec 31, 2022 | 100.73 Mn |
| Sep 30, 2022 | 104.54 Mn |
| Jun 30, 2022 | 82.60 Mn |
| Mar 31, 2022 | 77.59 Mn |
| Dec 31, 2021 | 22.94 Mn |
| Sep 30, 2021 | 22.45 Mn |